Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Clinical trial NCT06260553 · UNKNOWN

Trial details

NCT number: NCT06260553
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

EGFR/ ALK-negative Advanced NSCLC

Start date: 2024-02-07
Primary completion: 2025-02-07
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.